ArticleRadiology. Imaging cancer2022
Imaging Glioblastoma Metabolism by Using Hyperpolarized [1-
Open access · diamondAbstract read
In one paragraph
Article in Radiology. Imaging cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed, 1 pooled it
3.6field-weighted citation impact, top 6% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.
- Metabolic Imaging as Future Technology and Innovation in Brain-Tumour Surgery: A Systematic Review.Current oncology (Toronto, Ont.) · 2025Pooled it
- Enhanced Glioblastoma Detection ThroughMagnetic resonance in medicine · 2026Article
- Hyperpolarized MRI in Oncology-A Review of Clinical Studies and Evaluation of Preclinical Liver Studies.NMR in biomedicine · 2026Review
- A Static Phantom for Harmonization of Hyperpolarized [1-Magnetic resonance in medicine · 2026Article
- Quantitative Imaging of Pyruvate Metabolism in a Patient With Anaplastic Thyroid Cancer.Magnetic resonance in medicine · 2026Article
- Clinical Applications of Hyperpolarized Magnetic Resonance Imaging in Brain Tumors: Current Evidence and Future Opportunities.Cancers · 2026Review
- Absolute Quantification of Brain Deuterium Metabolic Imaging in Healthy Volunteers and Glioblastoma Patients at 7T.Magnetic resonance in medicine · 2026Article
- Lactate signaling and immune suppression in tumors: mechanisms and therapeutic implications.Cellular oncology (Dordrecht, Netherlands) · 2026Review
- Evaluation of treatment response in patients with recurrent grade 4 glioma using hyperpolarized [1-Research square · 2026Article
- Ultra-low fieldCommunications chemistry · 2026Article
- Technologies and Strategies for Metabolic and Molecular Imaging With Hyperpolarized MRI.Journal of magnetic resonance imaging : JMRI · 2026Review
- Clinical Translation of HyperpolarizedAJNR. American journal of neuroradiology · 2025Review
- Decoding Glioblastoma Heterogeneity: Neuroimaging Meets Machine Learning.Neurosurgery · 2025Review
- Temperature dependent chemical shifts of pyruvate and lactate enable in vivo hyperpolarizedNpj imaging · 2025Article
- Assessment of early response to neoadjuvant chemotherapy in multi-site high-grade serous ovarian cancer using hyperpolarized-EJNMMI research · 2025Article
- Quo Vadis HyperpolarizedZeitschrift fur medizinische Physik · 2025Review
- Carbon isotopic labelling of carboxylic acids enabled by organic photoredox-catalysed cyanation.Nature synthesis · 2025Article
- Article
- Deuterium Metabolic Imaging Differentiates Glioblastoma Metabolic Subtypes and Detects Early Response to Chemoradiotherapy.Cancer research · 2024Article
- Current methods for hyperpolarized [1-Magnetic resonance in medicine · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
33 authors at 3 institutions in 4 countries.
Fulvio ZaccagnaFrom the Departments of Radiology (F.Z., J.T.G., J.K., F.R., R.W., A.B.G., S.D., C.J.D., S.U., M.C.L., M.L., A.F., S.H., J.H.G., T.M., M.J.G., F.A.G.), Clinical Neurosciences (R.M., C.W., S.J.P., T.S.), and Medicine (I.W.), University of Cambridge School of Clinical Medicine, Cambridge, England; Cancer Research UK Cambridge Institute (M.A.M., S.U., K.M.B.), Medical Research Council Biostatistics Unit (J.W.), and Department of Biochemistry (K.M.B.), University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge, CB2 0RE, England; Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria (R.W.); GE Healthcare, Munich, Germany (R.F.S.); Department of Pathology (K.A.), Cambridge Cancer Trials Centre (A.C.), Department of Radiology (I.P., B.D.C., R.S.), and Department of Oncology (B.B., S.J.), Cambridge University Hospitals National Health Service Foundation Trust, Cambridge, England; and Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, England (J.W.).ORCID 0000-0001-6838-9532
Mary A McLeanFrom the Departments of Radiology (F.Z., J.T.G., J.K., F.R., R.W., A.B.G., S.D., C.J.D., S.U., M.C.L., M.L., A.F., S.H., J.H.G., T.M., M.J.G., F.A.G.), Clinical Neurosciences (R.M., C.W., S.J.P., T.S.), and Medicine (I.W.), University of Cambridge School of Clinical Medicine, Cambridge, England; Cancer Research UK Cambridge Institute (M.A.M., S.U., K.M.B.), Medical Research Council Biostatistics Unit (J.W.), and Department of Biochemistry (K.M.B.), University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge, CB2 0RE, England; Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria (R.W.); GE Healthcare, Munich, Germany (R.F.S.); Department of Pathology (K.A.), Cambridge Cancer Trials Centre (A.C.), Department of Radiology (I.P., B.D.C., R.S.), and Department of Oncology (B.B., S.J.), Cambridge University Hospitals National Health Service Foundation Trust, Cambridge, England; and Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, England (J.W.).ORCID 0000-0002-3752-0179
James T GristFrom the Departments of Radiology (F.Z., J.T.G., J.K., F.R., R.W., A.B.G., S.D., C.J.D., S.U., M.C.L., M.L., A.F., S.H., J.H.G., T.M., M.J.G., F.A.G.), Clinical Neurosciences (R.M., C.W., S.J.P., T.S.), and Medicine (I.W.), University of Cambridge School of Clinical Medicine, Cambridge, England; Cancer Research UK Cambridge Institute (M.A.M., S.U., K.M.B.), Medical Research Council Biostatistics Unit (J.W.), and Department of Biochemistry (K.M.B.), University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge, CB2 0RE, England; Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria (R.W.); GE Healthcare, Munich, Germany (R.F.S.); Department of Pathology (K.A.), Cambridge Cancer Trials Centre (A.C.), Department of Radiology (I.P., B.D.C., R.S.), and Department of Oncology (B.B., S.J.), Cambridge University Hospitals National Health Service Foundation Trust, Cambridge, England; and Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, England (J.W.).ORCID 0000-0001-7223-4031
Joshua KaggieFrom the Departments of Radiology (F.Z., J.T.G., J.K., F.R., R.W., A.B.G., S.D., C.J.D., S.U., M.C.L., M.L., A.F., S.H., J.H.G., T.M., M.J.G., F.A.G.), Clinical Neurosciences (R.M., C.W., S.J.P., T.S.), and Medicine (I.W.), University of Cambridge School of Clinical Medicine, Cambridge, England; Cancer Research UK Cambridge Institute (M.A.M., S.U., K.M.B.), Medical Research Council Biostatistics Unit (J.W.), and Department of Biochemistry (K.M.B.), University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge, CB2 0RE, England; Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria (R.W.); GE Healthcare, Munich, Germany (R.F.S.); Department of Pathology (K.A.), Cambridge Cancer Trials Centre (A.C.), Department of Radiology (I.P., B.D.C., R.S.), and Department of Oncology (B.B., S.J.), Cambridge University Hospitals National Health Service Foundation Trust, Cambridge, England; and Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, England (J.W.).ORCID 0000-0001-6706-3442
Richard MairFrom the Departments of Radiology (F.Z., J.T.G., J.K., F.R., R.W., A.B.G., S.D., C.J.D., S.U., M.C.L., M.L., A.F., S.H., J.H.G., T.M., M.J.G., F.A.G.), Clinical Neurosciences (R.M., C.W., S.J.P., T.S.), and Medicine (I.W.), University of Cambridge School of Clinical Medicine, Cambridge, England; Cancer Research UK Cambridge Institute (M.A.M., S.U., K.M.B.), Medical Research Council Biostatistics Unit (J.W.), and Department of Biochemistry (K.M.B.), University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge, CB2 0RE, England; Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria (R.W.); GE Healthcare, Munich, Germany (R.F.S.); Department of Pathology (K.A.), Cambridge Cancer Trials Centre (A.C.), Department of Radiology (I.P., B.D.C., R.S.), and Department of Oncology (B.B., S.J.), Cambridge University Hospitals National Health Service Foundation Trust, Cambridge, England; and Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, England (J.W.).
Frank RiemerFrom the Departments of Radiology (F.Z., J.T.G., J.K., F.R., R.W., A.B.G., S.D., C.J.D., S.U., M.C.L., M.L., A.F., S.H., J.H.G., T.M., M.J.G., F.A.G.), Clinical Neurosciences (R.M., C.W., S.J.P., T.S.), and Medicine (I.W.), University of Cambridge School of Clinical Medicine, Cambridge, England; Cancer Research UK Cambridge Institute (M.A.M., S.U., K.M.B.), Medical Research Council Biostatistics Unit (J.W.), and Department of Biochemistry (K.M.B.), University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge, CB2 0RE, England; Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria (R.W.); GE Healthcare, Munich, Germany (R.F.S.); Department of Pathology (K.A.), Cambridge Cancer Trials Centre (A.C.), Department of Radiology (I.P., B.D.C., R.S.), and Department of Oncology (B.B., S.J.), Cambridge University Hospitals National Health Service Foundation Trust, Cambridge, England; and Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, England (J.W.).
Ramona WoitekFrom the Departments of Radiology (F.Z., J.T.G., J.K., F.R., R.W., A.B.G., S.D., C.J.D., S.U., M.C.L., M.L., A.F., S.H., J.H.G., T.M., M.J.G., F.A.G.), Clinical Neurosciences (R.M., C.W., S.J.P., T.S.), and Medicine (I.W.), University of Cambridge School of Clinical Medicine, Cambridge, England; Cancer Research UK Cambridge Institute (M.A.M., S.U., K.M.B.), Medical Research Council Biostatistics Unit (J.W.), and Department of Biochemistry (K.M.B.), University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge, CB2 0RE, England; Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria (R.W.); GE Healthcare, Munich, Germany (R.F.S.); Department of Pathology (K.A.), Cambridge Cancer Trials Centre (A.C.), Department of Radiology (I.P., B.D.C., R.S.), and Department of Oncology (B.B., S.J.), Cambridge University Hospitals National Health Service Foundation Trust, Cambridge, England; and Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, England (J.W.).ORCID 0000-0002-9146-9159
Andrew B GillFrom the Departments of Radiology (F.Z., J.T.G., J.K., F.R., R.W., A.B.G., S.D., C.J.D., S.U., M.C.L., M.L., A.F., S.H., J.H.G., T.M., M.J.G., F.A.G.), Clinical Neurosciences (R.M., C.W., S.J.P., T.S.), and Medicine (I.W.), University of Cambridge School of Clinical Medicine, Cambridge, England; Cancer Research UK Cambridge Institute (M.A.M., S.U., K.M.B.), Medical Research Council Biostatistics Unit (J.W.), and Department of Biochemistry (K.M.B.), University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge, CB2 0RE, England; Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria (R.W.); GE Healthcare, Munich, Germany (R.F.S.); Department of Pathology (K.A.), Cambridge Cancer Trials Centre (A.C.), Department of Radiology (I.P., B.D.C., R.S.), and Department of Oncology (B.B., S.J.), Cambridge University Hospitals National Health Service Foundation Trust, Cambridge, England; and Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, England (J.W.).
Surrin DeenFrom the Departments of Radiology (F.Z., J.T.G., J.K., F.R., R.W., A.B.G., S.D., C.J.D., S.U., M.C.L., M.L., A.F., S.H., J.H.G., T.M., M.J.G., F.A.G.), Clinical Neurosciences (R.M., C.W., S.J.P., T.S.), and Medicine (I.W.), University of Cambridge School of Clinical Medicine, Cambridge, England; Cancer Research UK Cambridge Institute (M.A.M., S.U., K.M.B.), Medical Research Council Biostatistics Unit (J.W.), and Department of Biochemistry (K.M.B.), University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge, CB2 0RE, England; Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria (R.W.); GE Healthcare, Munich, Germany (R.F.S.); Department of Pathology (K.A.), Cambridge Cancer Trials Centre (A.C.), Department of Radiology (I.P., B.D.C., R.S.), and Department of Oncology (B.B., S.J.), Cambridge University Hospitals National Health Service Foundation Trust, Cambridge, England; and Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, England (J.W.).ORCID 0000-0002-6206-7337
Charlie J DanielsFrom the Departments of Radiology (F.Z., J.T.G., J.K., F.R., R.W., A.B.G., S.D., C.J.D., S.U., M.C.L., M.L., A.F., S.H., J.H.G., T.M., M.J.G., F.A.G.), Clinical Neurosciences (R.M., C.W., S.J.P., T.S.), and Medicine (I.W.), University of Cambridge School of Clinical Medicine, Cambridge, England; Cancer Research UK Cambridge Institute (M.A.M., S.U., K.M.B.), Medical Research Council Biostatistics Unit (J.W.), and Department of Biochemistry (K.M.B.), University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge, CB2 0RE, England; Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria (R.W.); GE Healthcare, Munich, Germany (R.F.S.); Department of Pathology (K.A.), Cambridge Cancer Trials Centre (A.C.), Department of Radiology (I.P., B.D.C., R.S.), and Department of Oncology (B.B., S.J.), Cambridge University Hospitals National Health Service Foundation Trust, Cambridge, England; and Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, England (J.W.).
Stephan UrsprungFrom the Departments of Radiology (F.Z., J.T.G., J.K., F.R., R.W., A.B.G., S.D., C.J.D., S.U., M.C.L., M.L., A.F., S.H., J.H.G., T.M., M.J.G., F.A.G.), Clinical Neurosciences (R.M., C.W., S.J.P., T.S.), and Medicine (I.W.), University of Cambridge School of Clinical Medicine, Cambridge, England; Cancer Research UK Cambridge Institute (M.A.M., S.U., K.M.B.), Medical Research Council Biostatistics Unit (J.W.), and Department of Biochemistry (K.M.B.), University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge, CB2 0RE, England; Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria (R.W.); GE Healthcare, Munich, Germany (R.F.S.); Department of Pathology (K.A.), Cambridge Cancer Trials Centre (A.C.), Department of Radiology (I.P., B.D.C., R.S.), and Department of Oncology (B.B., S.J.), Cambridge University Hospitals National Health Service Foundation Trust, Cambridge, England; and Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, England (J.W.).ORCID 0000-0003-2476-178X
Rolf F SchulteFrom the Departments of Radiology (F.Z., J.T.G., J.K., F.R., R.W., A.B.G., S.D., C.J.D., S.U., M.C.L., M.L., A.F., S.H., J.H.G., T.M., M.J.G., F.A.G.), Clinical Neurosciences (R.M., C.W., S.J.P., T.S.), and Medicine (I.W.), University of Cambridge School of Clinical Medicine, Cambridge, England; Cancer Research UK Cambridge Institute (M.A.M., S.U., K.M.B.), Medical Research Council Biostatistics Unit (J.W.), and Department of Biochemistry (K.M.B.), University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge, CB2 0RE, England; Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria (R.W.); GE Healthcare, Munich, Germany (R.F.S.); Department of Pathology (K.A.), Cambridge Cancer Trials Centre (A.C.), Department of Radiology (I.P., B.D.C., R.S.), and Department of Oncology (B.B., S.J.), Cambridge University Hospitals National Health Service Foundation Trust, Cambridge, England; and Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, England (J.W.).ORCID 0000-0002-1334-1264
Kieren AllinsonFrom the Departments of Radiology (F.Z., J.T.G., J.K., F.R., R.W., A.B.G., S.D., C.J.D., S.U., M.C.L., M.L., A.F., S.H., J.H.G., T.M., M.J.G., F.A.G.), Clinical Neurosciences (R.M., C.W., S.J.P., T.S.), and Medicine (I.W.), University of Cambridge School of Clinical Medicine, Cambridge, England; Cancer Research UK Cambridge Institute (M.A.M., S.U., K.M.B.), Medical Research Council Biostatistics Unit (J.W.), and Department of Biochemistry (K.M.B.), University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge, CB2 0RE, England; Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria (R.W.); GE Healthcare, Munich, Germany (R.F.S.); Department of Pathology (K.A.), Cambridge Cancer Trials Centre (A.C.), Department of Radiology (I.P., B.D.C., R.S.), and Department of Oncology (B.B., S.J.), Cambridge University Hospitals National Health Service Foundation Trust, Cambridge, England; and Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, England (J.W.).
Anita ChhabraFrom the Departments of Radiology (F.Z., J.T.G., J.K., F.R., R.W., A.B.G., S.D., C.J.D., S.U., M.C.L., M.L., A.F., S.H., J.H.G., T.M., M.J.G., F.A.G.), Clinical Neurosciences (R.M., C.W., S.J.P., T.S.), and Medicine (I.W.), University of Cambridge School of Clinical Medicine, Cambridge, England; Cancer Research UK Cambridge Institute (M.A.M., S.U., K.M.B.), Medical Research Council Biostatistics Unit (J.W.), and Department of Biochemistry (K.M.B.), University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge, CB2 0RE, England; Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria (R.W.); GE Healthcare, Munich, Germany (R.F.S.); Department of Pathology (K.A.), Cambridge Cancer Trials Centre (A.C.), Department of Radiology (I.P., B.D.C., R.S.), and Department of Oncology (B.B., S.J.), Cambridge University Hospitals National Health Service Foundation Trust, Cambridge, England; and Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, England (J.W.).ORCID 0000-0002-9899-8010
Marie-Christine LaurentFrom the Departments of Radiology (F.Z., J.T.G., J.K., F.R., R.W., A.B.G., S.D., C.J.D., S.U., M.C.L., M.L., A.F., S.H., J.H.G., T.M., M.J.G., F.A.G.), Clinical Neurosciences (R.M., C.W., S.J.P., T.S.), and Medicine (I.W.), University of Cambridge School of Clinical Medicine, Cambridge, England; Cancer Research UK Cambridge Institute (M.A.M., S.U., K.M.B.), Medical Research Council Biostatistics Unit (J.W.), and Department of Biochemistry (K.M.B.), University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge, CB2 0RE, England; Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria (R.W.); GE Healthcare, Munich, Germany (R.F.S.); Department of Pathology (K.A.), Cambridge Cancer Trials Centre (A.C.), Department of Radiology (I.P., B.D.C., R.S.), and Department of Oncology (B.B., S.J.), Cambridge University Hospitals National Health Service Foundation Trust, Cambridge, England; and Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, England (J.W.).
Matthew LockeFrom the Departments of Radiology (F.Z., J.T.G., J.K., F.R., R.W., A.B.G., S.D., C.J.D., S.U., M.C.L., M.L., A.F., S.H., J.H.G., T.M., M.J.G., F.A.G.), Clinical Neurosciences (R.M., C.W., S.J.P., T.S.), and Medicine (I.W.), University of Cambridge School of Clinical Medicine, Cambridge, England; Cancer Research UK Cambridge Institute (M.A.M., S.U., K.M.B.), Medical Research Council Biostatistics Unit (J.W.), and Department of Biochemistry (K.M.B.), University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge, CB2 0RE, England; Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria (R.W.); GE Healthcare, Munich, Germany (R.F.S.); Department of Pathology (K.A.), Cambridge Cancer Trials Centre (A.C.), Department of Radiology (I.P., B.D.C., R.S.), and Department of Oncology (B.B., S.J.), Cambridge University Hospitals National Health Service Foundation Trust, Cambridge, England; and Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, England (J.W.).ORCID 0000-0003-3481-2691
Amy FraryFrom the Departments of Radiology (F.Z., J.T.G., J.K., F.R., R.W., A.B.G., S.D., C.J.D., S.U., M.C.L., M.L., A.F., S.H., J.H.G., T.M., M.J.G., F.A.G.), Clinical Neurosciences (R.M., C.W., S.J.P., T.S.), and Medicine (I.W.), University of Cambridge School of Clinical Medicine, Cambridge, England; Cancer Research UK Cambridge Institute (M.A.M., S.U., K.M.B.), Medical Research Council Biostatistics Unit (J.W.), and Department of Biochemistry (K.M.B.), University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge, CB2 0RE, England; Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria (R.W.); GE Healthcare, Munich, Germany (R.F.S.); Department of Pathology (K.A.), Cambridge Cancer Trials Centre (A.C.), Department of Radiology (I.P., B.D.C., R.S.), and Department of Oncology (B.B., S.J.), Cambridge University Hospitals National Health Service Foundation Trust, Cambridge, England; and Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, England (J.W.).
Sarah HilborneFrom the Departments of Radiology (F.Z., J.T.G., J.K., F.R., R.W., A.B.G., S.D., C.J.D., S.U., M.C.L., M.L., A.F., S.H., J.H.G., T.M., M.J.G., F.A.G.), Clinical Neurosciences (R.M., C.W., S.J.P., T.S.), and Medicine (I.W.), University of Cambridge School of Clinical Medicine, Cambridge, England; Cancer Research UK Cambridge Institute (M.A.M., S.U., K.M.B.), Medical Research Council Biostatistics Unit (J.W.), and Department of Biochemistry (K.M.B.), University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge, CB2 0RE, England; Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria (R.W.); GE Healthcare, Munich, Germany (R.F.S.); Department of Pathology (K.A.), Cambridge Cancer Trials Centre (A.C.), Department of Radiology (I.P., B.D.C., R.S.), and Department of Oncology (B.B., S.J.), Cambridge University Hospitals National Health Service Foundation Trust, Cambridge, England; and Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, England (J.W.).ORCID 0000-0002-0790-020X
Ilse PattersonFrom the Departments of Radiology (F.Z., J.T.G., J.K., F.R., R.W., A.B.G., S.D., C.J.D., S.U., M.C.L., M.L., A.F., S.H., J.H.G., T.M., M.J.G., F.A.G.), Clinical Neurosciences (R.M., C.W., S.J.P., T.S.), and Medicine (I.W.), University of Cambridge School of Clinical Medicine, Cambridge, England; Cancer Research UK Cambridge Institute (M.A.M., S.U., K.M.B.), Medical Research Council Biostatistics Unit (J.W.), and Department of Biochemistry (K.M.B.), University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge, CB2 0RE, England; Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria (R.W.); GE Healthcare, Munich, Germany (R.F.S.); Department of Pathology (K.A.), Cambridge Cancer Trials Centre (A.C.), Department of Radiology (I.P., B.D.C., R.S.), and Department of Oncology (B.B., S.J.), Cambridge University Hospitals National Health Service Foundation Trust, Cambridge, England; and Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, England (J.W.).
Bruno D CarmoFrom the Departments of Radiology (F.Z., J.T.G., J.K., F.R., R.W., A.B.G., S.D., C.J.D., S.U., M.C.L., M.L., A.F., S.H., J.H.G., T.M., M.J.G., F.A.G.), Clinical Neurosciences (R.M., C.W., S.J.P., T.S.), and Medicine (I.W.), University of Cambridge School of Clinical Medicine, Cambridge, England; Cancer Research UK Cambridge Institute (M.A.M., S.U., K.M.B.), Medical Research Council Biostatistics Unit (J.W.), and Department of Biochemistry (K.M.B.), University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge, CB2 0RE, England; Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria (R.W.); GE Healthcare, Munich, Germany (R.F.S.); Department of Pathology (K.A.), Cambridge Cancer Trials Centre (A.C.), Department of Radiology (I.P., B.D.C., R.S.), and Department of Oncology (B.B., S.J.), Cambridge University Hospitals National Health Service Foundation Trust, Cambridge, England; and Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, England (J.W.).ORCID 0000-0003-2944-0766
Rhys SloughFrom the Departments of Radiology (F.Z., J.T.G., J.K., F.R., R.W., A.B.G., S.D., C.J.D., S.U., M.C.L., M.L., A.F., S.H., J.H.G., T.M., M.J.G., F.A.G.), Clinical Neurosciences (R.M., C.W., S.J.P., T.S.), and Medicine (I.W.), University of Cambridge School of Clinical Medicine, Cambridge, England; Cancer Research UK Cambridge Institute (M.A.M., S.U., K.M.B.), Medical Research Council Biostatistics Unit (J.W.), and Department of Biochemistry (K.M.B.), University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge, CB2 0RE, England; Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria (R.W.); GE Healthcare, Munich, Germany (R.F.S.); Department of Pathology (K.A.), Cambridge Cancer Trials Centre (A.C.), Department of Radiology (I.P., B.D.C., R.S.), and Department of Oncology (B.B., S.J.), Cambridge University Hospitals National Health Service Foundation Trust, Cambridge, England; and Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, England (J.W.).
Ian WilkinsonFrom the Departments of Radiology (F.Z., J.T.G., J.K., F.R., R.W., A.B.G., S.D., C.J.D., S.U., M.C.L., M.L., A.F., S.H., J.H.G., T.M., M.J.G., F.A.G.), Clinical Neurosciences (R.M., C.W., S.J.P., T.S.), and Medicine (I.W.), University of Cambridge School of Clinical Medicine, Cambridge, England; Cancer Research UK Cambridge Institute (M.A.M., S.U., K.M.B.), Medical Research Council Biostatistics Unit (J.W.), and Department of Biochemistry (K.M.B.), University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge, CB2 0RE, England; Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria (R.W.); GE Healthcare, Munich, Germany (R.F.S.); Department of Pathology (K.A.), Cambridge Cancer Trials Centre (A.C.), Department of Radiology (I.P., B.D.C., R.S.), and Department of Oncology (B.B., S.J.), Cambridge University Hospitals National Health Service Foundation Trust, Cambridge, England; and Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, England (J.W.).
Bristi BasuFrom the Departments of Radiology (F.Z., J.T.G., J.K., F.R., R.W., A.B.G., S.D., C.J.D., S.U., M.C.L., M.L., A.F., S.H., J.H.G., T.M., M.J.G., F.A.G.), Clinical Neurosciences (R.M., C.W., S.J.P., T.S.), and Medicine (I.W.), University of Cambridge School of Clinical Medicine, Cambridge, England; Cancer Research UK Cambridge Institute (M.A.M., S.U., K.M.B.), Medical Research Council Biostatistics Unit (J.W.), and Department of Biochemistry (K.M.B.), University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge, CB2 0RE, England; Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria (R.W.); GE Healthcare, Munich, Germany (R.F.S.); Department of Pathology (K.A.), Cambridge Cancer Trials Centre (A.C.), Department of Radiology (I.P., B.D.C., R.S.), and Department of Oncology (B.B., S.J.), Cambridge University Hospitals National Health Service Foundation Trust, Cambridge, England; and Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, England (J.W.).
James WasonFrom the Departments of Radiology (F.Z., J.T.G., J.K., F.R., R.W., A.B.G., S.D., C.J.D., S.U., M.C.L., M.L., A.F., S.H., J.H.G., T.M., M.J.G., F.A.G.), Clinical Neurosciences (R.M., C.W., S.J.P., T.S.), and Medicine (I.W.), University of Cambridge School of Clinical Medicine, Cambridge, England; Cancer Research UK Cambridge Institute (M.A.M., S.U., K.M.B.), Medical Research Council Biostatistics Unit (J.W.), and Department of Biochemistry (K.M.B.), University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge, CB2 0RE, England; Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria (R.W.); GE Healthcare, Munich, Germany (R.F.S.); Department of Pathology (K.A.), Cambridge Cancer Trials Centre (A.C.), Department of Radiology (I.P., B.D.C., R.S.), and Department of Oncology (B.B., S.J.), Cambridge University Hospitals National Health Service Foundation Trust, Cambridge, England; and Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, England (J.W.).
Jonathan H GillardFrom the Departments of Radiology (F.Z., J.T.G., J.K., F.R., R.W., A.B.G., S.D., C.J.D., S.U., M.C.L., M.L., A.F., S.H., J.H.G., T.M., M.J.G., F.A.G.), Clinical Neurosciences (R.M., C.W., S.J.P., T.S.), and Medicine (I.W.), University of Cambridge School of Clinical Medicine, Cambridge, England; Cancer Research UK Cambridge Institute (M.A.M., S.U., K.M.B.), Medical Research Council Biostatistics Unit (J.W.), and Department of Biochemistry (K.M.B.), University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge, CB2 0RE, England; Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria (R.W.); GE Healthcare, Munich, Germany (R.F.S.); Department of Pathology (K.A.), Cambridge Cancer Trials Centre (A.C.), Department of Radiology (I.P., B.D.C., R.S.), and Department of Oncology (B.B., S.J.), Cambridge University Hospitals National Health Service Foundation Trust, Cambridge, England; and Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, England (J.W.).
Tomasz MatysFrom the Departments of Radiology (F.Z., J.T.G., J.K., F.R., R.W., A.B.G., S.D., C.J.D., S.U., M.C.L., M.L., A.F., S.H., J.H.G., T.M., M.J.G., F.A.G.), Clinical Neurosciences (R.M., C.W., S.J.P., T.S.), and Medicine (I.W.), University of Cambridge School of Clinical Medicine, Cambridge, England; Cancer Research UK Cambridge Institute (M.A.M., S.U., K.M.B.), Medical Research Council Biostatistics Unit (J.W.), and Department of Biochemistry (K.M.B.), University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge, CB2 0RE, England; Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria (R.W.); GE Healthcare, Munich, Germany (R.F.S.); Department of Pathology (K.A.), Cambridge Cancer Trials Centre (A.C.), Department of Radiology (I.P., B.D.C., R.S.), and Department of Oncology (B.B., S.J.), Cambridge University Hospitals National Health Service Foundation Trust, Cambridge, England; and Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, England (J.W.).ORCID 0000-0003-2285-5715
Colin WattsFrom the Departments of Radiology (F.Z., J.T.G., J.K., F.R., R.W., A.B.G., S.D., C.J.D., S.U., M.C.L., M.L., A.F., S.H., J.H.G., T.M., M.J.G., F.A.G.), Clinical Neurosciences (R.M., C.W., S.J.P., T.S.), and Medicine (I.W.), University of Cambridge School of Clinical Medicine, Cambridge, England; Cancer Research UK Cambridge Institute (M.A.M., S.U., K.M.B.), Medical Research Council Biostatistics Unit (J.W.), and Department of Biochemistry (K.M.B.), University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge, CB2 0RE, England; Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria (R.W.); GE Healthcare, Munich, Germany (R.F.S.); Department of Pathology (K.A.), Cambridge Cancer Trials Centre (A.C.), Department of Radiology (I.P., B.D.C., R.S.), and Department of Oncology (B.B., S.J.), Cambridge University Hospitals National Health Service Foundation Trust, Cambridge, England; and Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, England (J.W.).
Stephen J PriceFrom the Departments of Radiology (F.Z., J.T.G., J.K., F.R., R.W., A.B.G., S.D., C.J.D., S.U., M.C.L., M.L., A.F., S.H., J.H.G., T.M., M.J.G., F.A.G.), Clinical Neurosciences (R.M., C.W., S.J.P., T.S.), and Medicine (I.W.), University of Cambridge School of Clinical Medicine, Cambridge, England; Cancer Research UK Cambridge Institute (M.A.M., S.U., K.M.B.), Medical Research Council Biostatistics Unit (J.W.), and Department of Biochemistry (K.M.B.), University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge, CB2 0RE, England; Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria (R.W.); GE Healthcare, Munich, Germany (R.F.S.); Department of Pathology (K.A.), Cambridge Cancer Trials Centre (A.C.), Department of Radiology (I.P., B.D.C., R.S.), and Department of Oncology (B.B., S.J.), Cambridge University Hospitals National Health Service Foundation Trust, Cambridge, England; and Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, England (J.W.).ORCID 0000-0002-7535-3009
Thomas SantariusFrom the Departments of Radiology (F.Z., J.T.G., J.K., F.R., R.W., A.B.G., S.D., C.J.D., S.U., M.C.L., M.L., A.F., S.H., J.H.G., T.M., M.J.G., F.A.G.), Clinical Neurosciences (R.M., C.W., S.J.P., T.S.), and Medicine (I.W.), University of Cambridge School of Clinical Medicine, Cambridge, England; Cancer Research UK Cambridge Institute (M.A.M., S.U., K.M.B.), Medical Research Council Biostatistics Unit (J.W.), and Department of Biochemistry (K.M.B.), University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge, CB2 0RE, England; Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria (R.W.); GE Healthcare, Munich, Germany (R.F.S.); Department of Pathology (K.A.), Cambridge Cancer Trials Centre (A.C.), Department of Radiology (I.P., B.D.C., R.S.), and Department of Oncology (B.B., S.J.), Cambridge University Hospitals National Health Service Foundation Trust, Cambridge, England; and Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, England (J.W.).
Martin J GravesFrom the Departments of Radiology (F.Z., J.T.G., J.K., F.R., R.W., A.B.G., S.D., C.J.D., S.U., M.C.L., M.L., A.F., S.H., J.H.G., T.M., M.J.G., F.A.G.), Clinical Neurosciences (R.M., C.W., S.J.P., T.S.), and Medicine (I.W.), University of Cambridge School of Clinical Medicine, Cambridge, England; Cancer Research UK Cambridge Institute (M.A.M., S.U., K.M.B.), Medical Research Council Biostatistics Unit (J.W.), and Department of Biochemistry (K.M.B.), University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge, CB2 0RE, England; Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria (R.W.); GE Healthcare, Munich, Germany (R.F.S.); Department of Pathology (K.A.), Cambridge Cancer Trials Centre (A.C.), Department of Radiology (I.P., B.D.C., R.S.), and Department of Oncology (B.B., S.J.), Cambridge University Hospitals National Health Service Foundation Trust, Cambridge, England; and Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, England (J.W.).
Sarah JefferiesFrom the Departments of Radiology (F.Z., J.T.G., J.K., F.R., R.W., A.B.G., S.D., C.J.D., S.U., M.C.L., M.L., A.F., S.H., J.H.G., T.M., M.J.G., F.A.G.), Clinical Neurosciences (R.M., C.W., S.J.P., T.S.), and Medicine (I.W.), University of Cambridge School of Clinical Medicine, Cambridge, England; Cancer Research UK Cambridge Institute (M.A.M., S.U., K.M.B.), Medical Research Council Biostatistics Unit (J.W.), and Department of Biochemistry (K.M.B.), University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge, CB2 0RE, England; Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria (R.W.); GE Healthcare, Munich, Germany (R.F.S.); Department of Pathology (K.A.), Cambridge Cancer Trials Centre (A.C.), Department of Radiology (I.P., B.D.C., R.S.), and Department of Oncology (B.B., S.J.), Cambridge University Hospitals National Health Service Foundation Trust, Cambridge, England; and Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, England (J.W.).
Kevin M BrindleFrom the Departments of Radiology (F.Z., J.T.G., J.K., F.R., R.W., A.B.G., S.D., C.J.D., S.U., M.C.L., M.L., A.F., S.H., J.H.G., T.M., M.J.G., F.A.G.), Clinical Neurosciences (R.M., C.W., S.J.P., T.S.), and Medicine (I.W.), University of Cambridge School of Clinical Medicine, Cambridge, England; Cancer Research UK Cambridge Institute (M.A.M., S.U., K.M.B.), Medical Research Council Biostatistics Unit (J.W.), and Department of Biochemistry (K.M.B.), University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge, CB2 0RE, England; Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria (R.W.); GE Healthcare, Munich, Germany (R.F.S.); Department of Pathology (K.A.), Cambridge Cancer Trials Centre (A.C.), Department of Radiology (I.P., B.D.C., R.S.), and Department of Oncology (B.B., S.J.), Cambridge University Hospitals National Health Service Foundation Trust, Cambridge, England; and Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, England (J.W.).ORCID 0000-0003-3883-6287
Ferdia A GallagherFrom the Departments of Radiology (F.Z., J.T.G., J.K., F.R., R.W., A.B.G., S.D., C.J.D., S.U., M.C.L., M.L., A.F., S.H., J.H.G., T.M., M.J.G., F.A.G.), Clinical Neurosciences (R.M., C.W., S.J.P., T.S.), and Medicine (I.W.), University of Cambridge School of Clinical Medicine, Cambridge, England; Cancer Research UK Cambridge Institute (M.A.M., S.U., K.M.B.), Medical Research Council Biostatistics Unit (J.W.), and Department of Biochemistry (K.M.B.), University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge, CB2 0RE, England; Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria (R.W.); GE Healthcare, Munich, Germany (R.F.S.); Department of Pathology (K.A.), Cambridge Cancer Trials Centre (A.C.), Department of Radiology (I.P., B.D.C., R.S.), and Department of Oncology (B.B., S.J.), Cambridge University Hospitals National Health Service Foundation Trust, Cambridge, England; and Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, England (J.W.).ORCID 0000-0003-4784-5230
University of Cambridge · GBNational Health Service · GBFaculty of 1000 (United Kingdom) · GB
Funding
Austrian Science Fund FWF J 4025Cancer Research UK 16465Cancer Research UK 28289Cancer Research UK A25040Cancer Research UK A29580Cancer Research UK C19212/A16628Cancer Research UK C19212/A911376Cancer Research UK C197/A16465Cancer Research UK C8742/A18097Cancer Research UK C9685/A25177Department of Health BRC-1215-20014Wellcome Trust
Abstract
Purpose To evaluate glioblastoma (GBM) metabolism by using hyperpolarized carbon 13 (
Indexed as
GlioblastomaBicarbonatesHumansLactate Dehydrogenase 5Lactic AcidMaleMiddle AgedProspective StudiesPyruvic AcidBicarbonatesLactate Dehydrogenase 5Lactic AcidPyruvic AcidCancerGlioblastomaHyperpolarized 13C MRIMetabolismMRINeuro-oncology
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.